Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HGSI/GSK's Benlysta Gets BLySfully Clean Labeling, Escaping Feared Restrictions

This article was originally published in The Pink Sheet Daily

Executive Summary

The indication is notable for what it does not contain, which is language specifically excluding African Americans or patients with severe active lupus nephritis or severe central nervous system lupus.
Advertisement

Related Content

Benlysta Is Niche, But Growing, So GSK's Not Giving Up On Lupus
Despite So-So Sales To Date, HGS Sees Promising Launch For Benlysta
GSK Battles Back With Strong 2Q Results, Says 2012 Will Be A Transformational Year
The Cabilly Saga: New Patent, New Product, New Lawsuits
HGS Anticipates Broad SLE Patient Access For Benlysta
Buoyed By Broad Labeling, HGSI Plans To Launch Benlysta In Two Weeks
With PDUFA Date Coming Up, HGSI Optimistically Outlines Launch Plans For Benlysta
With PDUFA Date Coming Up, HGSI Optimistically Outlines Launch Plans For Benlysta
Benlysta Decision Likely To Be Delayed By Negotiations On Labeling
Benlysta Back In The Spotlight With BLISS-76, But Second Phase III Still May Not Be Enough To Support Some Claims

Topics

Advertisement
UsernamePublicRestriction

Register

PS071934

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel